Di Liu

2.1k total citations · 1 hit paper
45 papers, 1.6k citations indexed

About

Di Liu is a scholar working on Nephrology, Molecular Biology and Biomedical Engineering. According to data from OpenAlex, Di Liu has authored 45 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Nephrology, 11 papers in Molecular Biology and 10 papers in Biomedical Engineering. Recurrent topics in Di Liu's work include Nanoplatforms for cancer theranostics (10 papers), Renal Diseases and Glomerulopathies (9 papers) and Acute Kidney Injury Research (8 papers). Di Liu is often cited by papers focused on Nanoplatforms for cancer theranostics (10 papers), Renal Diseases and Glomerulopathies (9 papers) and Acute Kidney Injury Research (8 papers). Di Liu collaborates with scholars based in China, United Kingdom and Czechia. Di Liu's co-authors include Yongzhong Du, Jing Qi, Gaofeng Shu, Feiyang Jin, Yan Du, Xiaoling Xu, Xiaoying Ying, Hui Yu, Saiping Jiang and Jiansong Ji and has published in prestigious journals such as Nature Communications, Nano Letters and ACS Nano.

In The Last Decade

Di Liu

45 papers receiving 1.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

ROS-responsive nano-drug delivery system combining mitochondria-targeting ceria nanoparticles with atorvastatin for acute kidney injury

2020 266 citations Hui Yu, Feiyang Jin et al. Theranostics profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Di Liu China	21	574	507	339	308	279	45	1.6k
Gaofeng Shu China	29	933 1.6×	775 1.5×	509 1.5×	190 0.6×	510 1.8×	68	2.8k
Huidan Zhang China	25	559 1.0×	745 1.5×	208 0.6×	46 0.1×	183 0.7×	73	1.9k
Jianglin Tan China	23	574 1.0×	389 0.8×	519 1.5×	60 0.2×	509 1.8×	53	2.4k
Xiaochen Gu Canada	29	380 0.7×	355 0.7×	193 0.6×	41 0.1×	442 1.6×	67	2.6k
He Lian China	24	660 1.1×	598 1.2×	140 0.4×	75 0.2×	683 2.4×	82	1.9k
Hiroshi Arakawa Japan	24	271 0.5×	431 0.9×	384 1.1×	103 0.3×	63 0.2×	115	2.2k
Aimei Li China	21	136 0.2×	664 1.3×	135 0.4×	229 0.7×	103 0.4×	73	1.8k
Yingying Zhang China	19	176 0.3×	360 0.7×	150 0.4×	101 0.3×	129 0.5×	96	1.3k
Songling Han China	20	497 0.9×	476 0.9×	337 1.0×	32 0.1×	413 1.5×	46	1.5k

Countries citing papers authored by Di Liu

Since Specialization

Citations

This map shows the geographic impact of Di Liu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Di Liu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Di Liu more than expected).

Fields of papers citing papers by Di Liu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Di Liu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Di Liu. The network helps show where Di Liu may publish in the future.

Co-authorship network of co-authors of Di Liu

This figure shows the co-authorship network connecting the top 25 collaborators of Di Liu. A scholar is included among the top collaborators of Di Liu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Di Liu. Di Liu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Li, Yuanyuan, et al.. (2024). Clinical rules of Acupoint selection for cancer pain opioid-induced constipation based on journal literature data mining: A systematic review. Heliyon. 10(5). e26170–e26170. 1 indexed citations

You, Yuchan, Feiyang Jin, Luwen Zhu, et al.. (2023). A photo-activable nano-agonist for the two-signal model of T cell in vivo activation. Journal of Controlled Release. 361. 681–693. 3 indexed citations

Liu, Di, Yanling Song, Hui Chen, et al.. (2023). Anti-VEGFR2 F(ab′)2 drug conjugate promotes renal accumulation and glomerular repair in diabetic nephropathy. Nature Communications. 14(1). 8268–8268. 7 indexed citations

Wu, Enyu, Xiao‐Wen Gu, Di Liu, et al.. (2023). Incorporation of multiple supramolecular binding sites into a robust MOF for benchmark one-step ethylene purification. Nature Communications. 14(1). 6146–6146. 101 indexed citations

Xia, Ming, Di Liu, Haiyang Liu, et al.. (2022). Identification of Hub Genes and Therapeutic Agents for IgA Nephropathy Through Bioinformatics Analysis and Experimental Validation. Frontiers in Medicine. 9. 881322–881322. 5 indexed citations

Yu, Pengcheng, Di Liu, Liang Fang, et al.. (2022). Thymopentin-Mediated Inhibition of Cancer Stem Cell Stemness Enhances the Cytotoxic Effect of Oxaliplatin on Colon Cancer Cells. Frontiers in Pharmacology. 13. 779715–779715. 4 indexed citations

Liu, Di, et al.. (2021). Recent advances in hepatocellular carcinoma therapeutic strategies and imaging-guided treatment. Journal of drug targeting. 30(3). 287–301. 9 indexed citations

Wang, Jun, Jing Qi, Feiyang Jin, et al.. (2021). Spatiotemporally light controlled “drug-free” macromolecules via upconversion-nanoparticle for precise tumor therapy. Nano Today. 42. 101360–101360. 16 indexed citations

Liu, Di, Yan Du, Yan Du, et al.. (2021). Renal Cell-Targeted Drug Delivery Strategy for Acute Kidney Injury and Chronic Kidney Disease: A Mini-Review. Molecular Pharmaceutics. 18(9). 3206–3222. 21 indexed citations

10.

Jin, Feiyang, Jing Qi, Di Liu, et al.. (2021). Cancer-cell-biomimetic Upconversion nanoparticles combining chemo-photodynamic therapy and CD73 blockade for metastatic triple-negative breast cancer. Journal of Controlled Release. 337. 90–104. 105 indexed citations

11.

Qi, Jing, Feiyang Jin, Yuchan You, et al.. (2021). Synergistic effect of tumor chemo-immunotherapy induced by leukocyte-hitchhiking thermal-sensitive micelles. Nature Communications. 12(1). 4755–4755. 122 indexed citations

12.

Wu, Lingzhi, Di Liu, Ming Xia, et al.. (2021). Immunofluorescence deposits in the mesangial area and glomerular capillary loops did not affect the prognosis of immunoglobulin a nephropathy except C1q:a single-center retrospective study. BMC Nephrology. 22(1). 43–43. 11 indexed citations

13.

Xu, Xiaoling, Nannan Zhang, Gaofeng Shu, et al.. (2021). A Luminol-Based Self-Illuminating Nanocage as a Reactive Oxygen Species Amplifier to Enhance Deep Tumor Penetration and Synergistic Therapy. ACS Nano. 15(12). 19394–19408. 58 indexed citations

14.

Jin, Feiyang, Jing Qi, Minxia Zhu, et al.. (2020). NIR-Triggered Sequentially Responsive Nanocarriers Amplified Cascade Synergistic Effect of Chemo-Photodynamic Therapy with Inspired Antitumor Immunity. ACS Applied Materials & Interfaces. 12(29). 32372–32387. 43 indexed citations

15.

Qi, Jing, Xiaoling Xu, Feiyang Jin, et al.. (2020). Cyto-friendly polymerization at cell surfaces modulates cell fate by clustering cell-surface receptors. Chemical Science. 11(16). 4221–4225. 26 indexed citations

16.

Liu, Di, Gaofeng Shu, Feiyang Jin, et al.. (2020). ROS-responsive chitosan-SS31 prodrug for AKI therapy via rapid distribution in the kidney and long-term retention in the renal tubule. Science Advances. 6(41). 161 indexed citations

17.

Yu, Hui, Feiyang Jin, Di Liu, et al.. (2020). ROS-responsive nano-drug delivery system combining mitochondria-targeting ceria nanoparticles with atorvastatin for acute kidney injury. Theranostics. 10(5). 2342–2357. 266 indexed citations breakdown →

18.

Xu, Xiaoling, Xu-Qi Kang, Jing Qi, et al.. (2019). Novel Antibacterial Strategies for Combating Bacterial Multidrug Resistance. Current Pharmaceutical Design. 25(44). 4717–4724. 9 indexed citations

19.

Kang, Xu-Qi, Gaofeng Shu, Saiping Jiang, et al.. (2019). Effective targeted therapy for drug-resistant infection by ICAM-1 antibody-conjugated TPGS modified β-Ga₂O₃:Cr³⁺ nanoparticles. Theranostics. 9(10). 2739–2753. 20 indexed citations

20.

Zheng, Beiwen, Shuguang Tan, Jia Gao, et al.. (2011). An unexpected similarity between antibiotic-resistant NDM-1 and beta-lactamase II from Erythrobacter litoralis. Protein & Cell. 2(3). 250–258. 31 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact